PAR:OSE

OSE Immunotherapeutics S.A. · PAR · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-07 13:19 UTC

Last close

n/aEUR

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-1439.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
-1303.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed

Growth is the furthest below its sector's middle: 0.07 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.14x

5.94x

6.44x

1.41x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.14x
Its own average over 10 years, 18.7M.
Profit5.94x
Its own average over 10 years, -6.3M.
Free cash flow6.44x
Its own average over 10 years, -5.3M.
Debt1.41x
Its own average over 10 years, 25.1M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 6.44 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Profit	Shares in issue
2016-12-31	100.0	100.0	100.0
2017-12-31	1,744.6	-50.8	105.7
2018-12-31	6,385.4	26.6	114.2
2019-12-31	6,776.0	-22.5	109.6
2020-12-31	2,720.1	-80.1	114.5
2021-12-31	6,868.4	-81.5	133.6
2022-12-31	4,778.6	-85.9	135.8
2023-12-31	581.5	-111.3	144.0
2024-12-31	18,244.6	181.2	160.5
2025-12-31	683.8	-182.4	164.2

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: EUR

How profit was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: EUR

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: EUR

Figures behind the shape

Growth

-24.1%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate-24.1%
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
One-year change in net income-200.7%
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed

Returns on capital

-137.9%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity-137.9%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets-48.1%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

100.0%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross margin100.0%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin-1835.0%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin-1439.5%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin-1303.3%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

1.4x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
- Computed from the filing for 2025
Price to book1.4x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio14.6x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

1.28

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio1.28
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score-2.39
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-07
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
EUR
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.